top of page
Retatrutide
Retatrutide is in phase 2 trials for obesity developed by American pharmaceutical company Eli Lilly and Company. It is triple hormone receptor against GLP-1, GIP, and GCGR receptors. It has been shown to achieve a more than 24% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during the phase 2 trail. The drug is a peptide with amino acid sequence.
Retatrutide is in phase 2 trials for obesity developed by American pharmaceutical company Eli Lilly and Company. It is triple hormone receptor against GLP-1, GIP, and GCGR receptors. It has been shown to achieve a more than 24% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during the phase 2 trail. The drug is a peptide with amino acid sequence.…
1 product
bottom of page